Tesamorelin
MetabolicAlso known as Egrifta, TH9507
Evidence tier
Regulator-reviewed human evidence
2 human trials · 1 review · 1 observational
- Researched since
- 2003
- Publications
- 120
- Mean purity
- 99.7%
- Vendors listing
- 26
NeuroLabs Research shows the highest mean assayed purity for Tesamorelin at 99.9% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2003 — 23 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
120 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 37 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.25 pts purity across lots, mean label deviation 15.7%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
26 of 26 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
35 of 37 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Tesamorelin?
A stabilised analogue of growth-hormone-releasing hormone, approved to reduce excess visceral abdominal fat in a specific clinical population.
Studied in published research for reducing visceral abdominal fat and growth-hormone release.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Approved as a medicine (Egrifta) and studied in human trials of visceral fat reduction. PepIndex does not evaluate clinical significance and does not describe administration.
- Tesamorelin — PubMed (2012)
Peer-reviewed article indexed in PubMed, published in PubMed (2012).
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors — AIDS (London, England) (2024)
Peer-reviewed article indexed in PubMed, published in AIDS (London, England) (2024).
- Tesamorelin — Nature reviews. Drug discovery (2011)
Peer-reviewed article indexed in PubMed, published in Nature reviews. Drug discovery (2011).
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — The Annals of pharmacotherapy (2012)
Peer-reviewed article indexed in PubMed, published in The Annals of pharmacotherapy (2012).
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs (2011)
Peer-reviewed article indexed in PubMed, published in Drugs (2011).
- Tesamorelin update — BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation (2010)
Peer-reviewed article indexed in PubMed, published in BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation (2010).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Tesamorelin, a human growth hormone releasing factor analogue — Expert opinion on investigational drugs (2009)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2009).
Indexed studies4 human-evidence of 4
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors — Human — controlled trial, 2024
Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy. We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo amon…
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials — Meta-analysis, 2026
HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been proposed as a targeted therapy. We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorel…
- Approach to the Patient With Lipodystrophy — Case report, 2022
Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in maintenance of metabolic homeostasis, fat deficiency in lipodystrophy typically leads to profound metabolic disturbances including insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. While rare, recent genetic studies indicate that lipodystrophy is more prevalent than has been previously thought, sugg…
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity — Human — controlled trial, 2025
In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression. This 6-month phase 2 randomized open-label clinical trial compared tesam…
Evidence digest
What the research on Tesamorelin actually shows
The indexed literature on Tesamorelin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tesamorelin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| CuroISO/IEC 17025 | 93.877% | — | 1 | 99.8% | 23.0% | |
| Polaris PeptidesISO/IEC 17025 | 93.877% | — | 3 | 99.4% | 14.1% | |
| Ascend ScienceISO/IEC 17025 | 90.291% | $5.60 (64%) | 3 | 99.6% | 16.2% | |
| PeptidePlugs | 89.790% | — | 4 | 99.8% | 12.2% | |
| Protide Health | 86.294% | $7.75 (89%) | 0 | — | — | |
| NeuroLabs Research | 82.186% | $7.00 (80%) | 1 | 99.9% | 33.0% | |
| Origin Labs | 81.885% | — | 1 | 99.9% | 11.1% | |
| Northline LabsISO/IEC 17025 | 79.493% | — | 1 | 99.2% | 1.2% | |
| ZC Labs | 79.384% | — | 4 | 99.6% | 10.8% | |
| Koi Peptides | 79.294% | $9.00 (103%) | 0 | — | — | |
| Good Science Bio | 79.275% | $2.00 (30%) | 0 | — | — | |
| American PeptidesISO/IEC 17025 | 79.1100% | $12.00 (137%) | 3 | 99.9% | 9.1% | |
| Licensed Peptides | 7789% | — | 1 | 99.0% | 14.0% | |
| Peptime | 75.359% | — | 1 | 99.9% | 13.9% | |
| Ascension Peptides | 75.286% | $10.00 (114%) | 1 | 99.9% | 16.6% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 2 | 99.8% | 9.6% | |
| Simple Peptide | 7489% | — | 2 | 99.7% | 45.5% | |
| Next Gen PeptidesISO/IEC 17025 | 73.897% | $19.75 (226%) | 6 | 99.7% | 9.4% | |
| Vertex Labs | 70.170% | — | 1 | 99.8% | 16.0% | |
| Disguised Alpha | 7070% | $8.00 (91%) | 0 | — | — | |
| BioLongevity Labs | 67.274% | $10.94 (125%) | 0 | — | — | |
| Eternal Peptides | 66.665% | $8.50 (97%) | 0 | — | — | |
| Mile High Compounds | 65.894% | $8.00 (91%) | 0 | — | — | |
| Extreme Peptides | 64.282% | — | 1 | 99.6% | 0.0% | |
| Improved Peptides | 5789% | $17.80 (203%) | 1 | 99.7% | 75.4% | |
| Sports Technology Labs | 54.974% | $17.00 (194%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| ZC Labs | ZCLa2608070015 | Freedom Diagnostics Testing | 10 mg | 10 mg | 0.0% | 100.0% | Vendor-published | |
| ZC Labs | ZCLa2607301113 | Freedom Diagnostics Testing | 10 mg | 11.93 mg | 19.3% | 99.1% | Vendor-published | |
| Origin Labs | Orig2607270907 | Freedom Diagnostics Testing | 20 mg | 22.22 mg | 11.1% | 99.9% | Vendor-published | |
| ZC Labs | ZCLa2607240722 | Freedom Diagnostics Testing | 10 mg | 11.18 mg | 11.8% | 99.8% | Vendor-published | |
| Ascend Science | AS-TSM10-2 | ILS Labs | 10 mg | 10.43 mg | 4.3% | 99.8% | Vendor-published | |
| Peptime | 71TE | Freedom Diagnostics Testing | 10 mg | 11.39 mg | 13.9% | 99.9% | Vendor-published | |
| NeuroLabs Research | NL01-TESA10R | Analysis FreedomDiagnostics | 10 mg | 13.3 mg | 33.0% | 99.9% | Vendor-published | |
| Ascend Science | AS-TSM20 | Kovera Labs | 20 mg | 19.99 mg | 0.1% | 99.5% | Vendor-published | |
| PeptidePlugs | 160-310X-DK | Freedom Diagnostics Testing | 10 mg | 10.99 mg | 9.9% | 99.9% | Vendor-published | |
| Curo | TSM20ZO626 | BTLabs | 20 mg | 24.6 mg | 23.0% | 99.8% | Vendor-published | |
| Ascend Science | AS-TSM5 | Kovera Labs and/or ILS Labs | 10 mg | 5.58 mg | 44.2% | 99.6% | Vendor-published | |
| Next Gen Peptides | TIC16-09 | ILS Laboratories | 16 mg | 16.62 mg | 3.9% | 99.8% | Vendor-published | |
| Next Gen Peptides | TSM-13 | ILS Laboratories | 10 mg | 10.48 mg | 4.8% | 99.6% | Vendor-published | |
| Vertex Labs | 2607010625 | Freedom Diagnostics Testing | 10 mg | 11.6 mg | 16.0% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-K8V8 | Analysis FreedomDiagnostics | 10 mg | 11.45 mg | 14.5% | 99.9% | Vendor-published | |
| Next Gen Peptides | tsm20-04 | ILS Laboratories | 20 mg | 20.67 mg | 3.4% | 100.0% | Vendor-published | |
| PeptidePlugs | 143-02-DK-SLV | Freedom Diagnostics Testing | 10 mg | 10.64 mg | 6.4% | 99.9% | Vendor-published | |
| PeptidePlugs | 136-02-SM-WT | Freedom Diagnostics Testing | 10 mg | 10.17 mg | 1.7% | 99.8% | Vendor-published | |
| American Peptides | TESA20-0528 | Bioviridian Inc. | 20 mg | 20.72 mg | 3.6% | 99.9% | Vendor-published | |
| American Peptides | TESA10-0528 | Bioviridian Inc. | 10 mg | 10.66 mg | 6.6% | 99.9% | Vendor-published | |
| Simple Peptide | TES10-062026-1 | Analysis FreedomDiagnostics | 10 mg | 11.72 mg | 17.2% | 99.7% | Vendor-published | |
| ZC Labs | ZCLa2606080087 | Freedom Diagnostics Testing | 10 mg | 11.22 mg | 12.2% | 99.7% | Vendor-published | |
| Modern Aminos | BX-P-D7F4 | Analysis FreedomDiagnostics | 5 mg | 5.24 mg | 4.8% | 99.7% | Vendor-published | |
| Simple Peptide | TSIP14-052026-1 | Analysis FreedomDiagnostics | 12 mg | 3.15 mg | 73.8% | 99.7% | Vendor-published | |
| Next Gen Peptides | TSM20-3 | ILS Laboratories | 20 mg | 20.71 mg | 3.6% | 99.5% | Vendor-published | |
| Northline Labs | NLL-7980975 | horizonanalytical.com | 10 mg | 10.12 mg | 1.2% | 99.2% | Vendor-published | |
| Improved Peptides | IP-TESA-2026-001 | Not named on certificate | 5 mg | 1.23 mg | 75.4% | 99.7% | Vendor-published | |
| Next Gen Peptides | Number | ILS Laboratories | 10 mg | 13.65 mg | 36.5% | 100.0% | Vendor-published | |
| Next Gen Peptides | TSM11 | ILS Laboratories | 10 mg | 10.44 mg | 4.4% | 99.4% | Vendor-published | |
| Polaris Peptides | POL-TESA10-8 | TrustPointe Analytics LLC | 10 mg | 11.19 mg | 11.9% | 99.2% | Vendor-published | |
| American Peptides | TESA10-0318 | Excellence in HPLC-MS Analysis | 10 mg | 11.71 mg | 17.1% | 99.8% | Vendor-published | |
| PeptidePlugs | 2602150177 | Freedom Diagnostics Testing | 10 mg | 13.09 mg | 30.9% | 99.7% | Vendor-published | |
| Ascension Peptides | 32-01260229 | MZ Biolabs | 5 mg | 5.83 mg | 16.6% | 99.9% | Vendor-published | |
| Extreme Peptides | EXT-TESA-00005 | Richard Sylvester MD | 2.74 mg | 2.74 mg | 0.0% | 99.6% | Vendor-published | |
| Licensed Peptides | TESA120625 | Vanguard Laboratory | 10 mg | 11.4 mg | 14.0% | 99.0% | Vendor-published | |
| Polaris Peptides | POL-TESA10-6 | TrustPointe Analytics LLC | 10 mg | 11.98 mg | 19.8% | 99.3% | Vendor-published | |
| Polaris Peptides | POL-TESA10-5 | TrustPointe Analytics LLC | 10 mg | 11.07 mg | 10.7% | 99.8% | Vendor-published |